Vir Biotechnology Net Worth
Vir Biotechnology Net Worth Breakdown | VIR |
Vir Biotechnology Net Worth Analysis
Vir Biotechnology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vir Biotechnology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vir Biotechnology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vir Biotechnology's net worth analysis. One common approach is to calculate Vir Biotechnology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vir Biotechnology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vir Biotechnology's net worth. This approach calculates the present value of Vir Biotechnology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vir Biotechnology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vir Biotechnology's net worth. This involves comparing Vir Biotechnology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vir Biotechnology's net worth relative to its peers.
Enterprise Value |
|
To determine if Vir Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vir Biotechnology's net worth research are outlined below:
| Vir Biotechnology had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 74.2 M. Reported Net Loss for the year was (521.96 M) with loss before taxes, overhead, and interest of (427.98 M). | |
| Vir Biotechnology has about 2.2 B in cash with (446.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 80.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway into mid-2027 as ECLIPSE 1 completes enrollment early |
Vir Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vir Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vir Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Vir Biotechnology Target Price Consensus
Vir target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Vir Biotechnology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Buy |
Most Vir analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Vir stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Vir Biotechnology, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVir Biotechnology Target Price Projection
Vir Biotechnology's current and average target prices are 5.70 and 17.22, respectively. The current price of Vir Biotechnology is the price at which Vir Biotechnology is currently trading. On the other hand, Vir Biotechnology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Vir Biotechnology Market Quote on 12th of November 2025
Target Price
Analyst Consensus On Vir Biotechnology Target Price
Know Vir Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vir Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vir Biotechnology backward and forwards among themselves. Vir Biotechnology's institutional investor refers to the entity that pools money to purchase Vir Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Charles Schwab Investment Management Inc | 2025-06-30 | 1.3 M | Goldman Sachs Group Inc | 2025-06-30 | 1.3 M | Ikarian Capital, Llc | 2025-06-30 | 1.1 M | Renaissance Technologies Corp | 2025-06-30 | 1.1 M | Aberdeen Group Plc | 2025-06-30 | 1 M | Northern Trust Corp | 2025-06-30 | 928.2 K | Schroder Investment Management Group | 2025-06-30 | 840.4 K | Artisan Partners Limited Partnership | 2025-06-30 | 791.6 K | Voloridge Investment Management, Llc | 2025-06-30 | 789.5 K | Sb Investment Advisers (uk) Ltd | 2025-06-30 | 16.7 M | Blackrock Inc | 2025-06-30 | 16.2 M |
Follow Vir Biotechnology's market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 794.4 M.Market Cap |
|
Project Vir Biotechnology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.46) | (0.44) | |
| Return On Assets | (0.37) | (0.35) | |
| Return On Equity | (0.45) | (0.43) |
When accessing Vir Biotechnology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vir Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vir Biotechnology's profitability and make more informed investment decisions.
Evaluate Vir Biotechnology's management efficiency
Vir Biotechnology has Return on Asset of (0.2597) % which means that on every $100 spent on assets, it lost $0.2597. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4906) %, meaning that it generated no profit with money invested by stockholders. Vir Biotechnology's management efficiency ratios could be used to measure how well Vir Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/12/2025, Return On Tangible Assets is likely to drop to -0.4. In addition to that, Return On Capital Employed is likely to grow to -0.44. At this time, Vir Biotechnology's Net Tangible Assets are relatively stable compared to the past year. As of 11/12/2025, Non Currrent Assets Other is likely to grow to about 19.3 M, while Non Current Assets Total are likely to drop slightly above 240.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.44 | 4.52 | |
| Tangible Book Value Per Share | 8.26 | 8.67 | |
| Enterprise Value Over EBITDA | (1.63) | (1.71) | |
| Price Book Value Ratio | 0.87 | 0.58 | |
| Enterprise Value Multiple | (1.63) | (1.71) | |
| Price Fair Value | 0.87 | 0.58 | |
| Enterprise Value | 1.1 B | 1.6 B |
The operational strategies employed by Vir Biotechnology management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 24.3735 | Revenue | Quarterly Revenue Growth (0.90) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vir Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vir Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vir Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vir Biotechnology Corporate Filings
F4 | 7th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 5th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Vir Biotechnology Earnings Estimation Breakdown
The calculation of Vir Biotechnology's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vir Biotechnology is estimated to be -0.88275 with the future projection ranging from a low of -0.90375 to a high of -0.84. Please be aware that this consensus of annual earnings estimates for Vir Biotechnology is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.9 Lowest | Expected EPS | -0.84 Highest |
Vir Biotechnology Earnings Projection Consensus
Suppose the current estimates of Vir Biotechnology's value are higher than the current market price of the Vir Biotechnology stock. In this case, investors may conclude that Vir Biotechnology is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vir Biotechnology's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 9 | 82.96% | -1.17 | -0.88275 | -3.62 |
Vir Biotechnology Earnings per Share Projection vs Actual
Actual Earning per Share of Vir Biotechnology refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vir Biotechnology predict the company's earnings will be in the future. The higher the earnings per share of Vir Biotechnology, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Vir Biotechnology Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Vir Biotechnology, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vir Biotechnology should always be considered in relation to other companies to make a more educated investment decision.Vir Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Vir Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-10-30 | 2025-09-30 | -0.8407 | -1.17 | -0.3293 | 39 | ||
2025-07-30 | 2025-06-30 | -0.7754 | -0.8 | -0.0246 | 3 | ||
2025-04-30 | 2025-03-31 | -0.8433 | -0.88 | -0.0367 | 4 | ||
2025-02-20 | 2024-12-31 | -0.89 | -0.76 | 0.13 | 14 | ||
2024-10-31 | 2024-09-30 | -1.05 | -1.56 | -0.51 | 48 | ||
2024-08-01 | 2024-06-30 | -0.9 | -1.02 | -0.12 | 13 | ||
2024-05-02 | 2024-03-31 | -1.05 | -0.48 | 0.57 | 54 | ||
2024-02-22 | 2023-12-31 | -1.01 | -0.86 | 0.15 | 14 | ||
2023-11-02 | 2023-09-30 | -1.21 | -1.22 | -0.01 | 0 | ||
2023-08-03 | 2023-06-30 | -1.2 | -1.45 | -0.25 | 20 | ||
2023-05-04 | 2023-03-31 | -0.87 | -1.06 | -0.19 | 21 | ||
2023-02-23 | 2022-12-31 | -0.39 | -0.76 | -0.37 | 94 | ||
2022-11-03 | 2022-09-30 | -0.21 | 1.3 | 1.51 | 719 | ||
2022-08-09 | 2022-06-30 | 0.1 | -0.58 | -0.68 | 680 | ||
2022-05-05 | 2022-03-31 | 3.78 | 3.85 | 0.07 | 1 | ||
2022-02-24 | 2021-12-31 | 3.04 | 3.92 | 0.88 | 28 | ||
2021-11-04 | 2021-09-30 | 0.02 | 0.82 | 0.8 | 4000 | ||
2021-08-05 | 2021-06-30 | -0.48 | 0.46 | 0.94 | 195 | ||
2021-05-06 | 2021-03-31 | -0.21 | -1.32 | -1.11 | 528 | ||
2021-02-25 | 2020-12-31 | -0.7 | -0.83 | -0.13 | 18 | ||
2020-11-10 | 2020-09-30 | -0.6 | -0.67 | -0.07 | 11 | ||
2020-08-11 | 2020-06-30 | -0.62 | -0.27 | 0.35 | 56 | ||
2020-05-12 | 2020-03-31 | -0.53 | -0.71 | -0.18 | 33 | ||
2020-03-26 | 2019-12-31 | -0.67 | -0.69 | -0.02 | 2 | ||
2019-11-19 | 2019-09-30 | -3.71 | -4.6 | -0.89 | 23 | ||
2019-08-28 | 2019-06-30 | -0.71 | -0.705 | 0.005 | 0 |
Vir Biotechnology Corporate Management
| Pr MD | SVP Fellow | Profile | |
| Klaus Frueh | CoFounder Advisor | Profile | |
| George Scangos | CEO Pres | Profile | |
| Louis MD | CoFounder Advisor | Profile | |
| Jeff MD | Executive Officer | Profile | |
| Arran Attridge | Senior Communications | Profile |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.